The INCATE Selection Committee selected the last 4 new ventures for Stage I support in 2023. The selected ventures are:

• PhageOne – Building am integrated company for Phage Therapy
• Paerublock (Helmholtz Institute for Pharmaceutical Research) –  develops non-traditional small molecules targeting elastase (LasB) from Pseudomonas aeruginosa as novel antibiotic therapeutics
• CorA (University Hospital Bonn + Helmholtz Centre for Infection Research) – The University Hospital Bonn together with Helmholtz Centre for Infection research develops the natural compound Corallopyronin A for difficult-to-treat Gram-positive infections, with funding from DZIF.
• Puray – Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients.

Information on the other companies selected in previous stage I applications are on the portfolio page.